TABLE 1.
Number of strains initially screened for evidence of growth on 8 μg of fluconazole per mla
| Serotype | MLEE genotype | Prevalence (%)b | Total no. of strains | No. of strains that did not growg | No. of strains that grewg |
|---|---|---|---|---|---|
| A | ET-1 | 69 | 31 | 4 | 27 |
| ET-2 | 10 | 10 | 3 | 7 | |
| ET-3 | 5 | 5 | 5 | 0 | |
| ET-4 | 4 | 2 | 0 | 2 | |
| Unknown | 4 | 0 | 4 | ||
| AD | ET-5 | 6c | 3 | 0 | 3 |
| ET-6 | NAd | 1 | 0 | 1 | |
| ET-7 | 6c | 4 | 0 | 4 | |
| ET-21 | 6c | 5 | 0 | 5 | |
| D | ET-8 | 3e | 7 | 2 | 5 |
| ET-9 | 3e | 3 | 1 | 2 | |
| ET-10 | NA | 1 | 0 | 1 | |
| ET-11 | NA | 1 | 1 | 0 | |
| ET-12 | 3e | 3 | 3 | 0 | |
| Unknown | 4 | 0 | 4 | ||
| C | ET-13 | NA | 1 | 0 | 1 |
| ET-16 | NA | 2 | 0 | 2 | |
| B | ET-14 | NA | 1 | 0 | 1 |
| ET-15 | NA | 2 | 0 | 2 | |
| ET-17 | NA | 1 | 0 | 1 | |
| ET-18 | 1f | 2 | 0 | 2 | |
| ET-19 | NA | 1 | 1 | 0 | |
| Unknown | 5 | 1 | 4 | ||
| Unclear | Unknown | 2 | 0 | 2 | |
| Total | 101 | 21 | 80 |
b
Prevalence of each ET (enzyme type) in four regions of the United States as determined by active surveillance (8).
c
The prevalence of ET-5, ET-7, and ET-21 was determined as a group.
d
NA, not available.
e
The prevalence of ET-8, ET-9, and ET-12 was determined as a group.
f
The prevalence of ET-18, ET-29, and ET-30 was determined as a group.
g
Growth medium is YMA with 8 μg of fluconazole per ml.